Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Topotecan, Cyclophosphamide and Melphalan in Multiple Myeloma
NCT01039025Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2002
- Primary completion
- May 2006
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of topotecan liposome, cyclophosphamide, melphalan in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2002; status: completed.
02
Drugs
topotecan liposomecyclophosphamidemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01039025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01039025.